Trials / Unknown
UnknownNCT06122181
Study of HS-10384 in Participants of Chinese Postmenopausal Women
A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HS-10384 in Chinese Postmenopausal Women
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Hansoh BioMedical R&D Company · Industry
- Sex
- Female
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
A randomized, double-blind, placebo-controlled phase Ib clinical study to evaluate the safety, tolerability and pharmacokinetics characteristics of HS-10384 in Chinese postmenopausal women.
Detailed description
Phase Ib is consisted with 3\~4 multiple ascending doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-10384 tablets | Multiple dosing of HS-10384 orally in a fasting state |
| DRUG | HS-10384-matched placebo tablets | Multiple dosing of HS-10384-matched placebo orally in a fasting state |
Timeline
- Start date
- 2023-11-12
- Primary completion
- 2024-06-30
- Completion
- 2024-09-30
- First posted
- 2023-11-08
- Last updated
- 2024-03-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06122181. Inclusion in this directory is not an endorsement.